Institute of Cancer Research The Royal Marsden

Surrey, United Kingdom

Institute of Cancer Research The Royal Marsden

Surrey, United Kingdom

Time filter

Source Type

Molife L.R.,Institute of Cancer Research The Royal Marsden | De Bono J.S.,Institute of Cancer Research The Royal Marsden
Expert Opinion on Investigational Drugs | Year: 2011

Introduction: Histone deacetylase (HDAC) inhibitors have recently emerged as a novel and active class of anticancer agents. Belinostat is one member of the class that has been tested as a single agent and in combination with other chemotherapies and biological agents in the treatment of solid tumors and lymphoma. Areas covered: A literature search of pre-clinical and clinical studies of belinostat was performed. The data from these studies were analysed to summarise the progress of belinostat from Phase I to a current pivotal trial in peripheral T-cell lymphoma. The parallel development of appropriate biomarker analysis is also discussed. Expert opinion: Belinostat has demonstrated significant clinical activity in T-cell lymphomas. Although its activity as a single agent in solid tumors has been less compelling, the emerging results from combination trials are promising. However, the basis for the activity of belinostat, like that of other HDAC inhibitors, remains to be truly defined and the identification of predictive and prognostic biomarkers of activity should be established to further progress the development of this compound. © 2011 Informa UK, Ltd.

Loading Institute of Cancer Research The Royal Marsden collaborators
Loading Institute of Cancer Research The Royal Marsden collaborators